Vancomycin Clearance in High-Volume Venovenous Hemofiltration

被引:15
作者
Paciullo, Christopher A. [1 ,2 ]
Harned, Kevin C. [3 ]
Davis, George A. [4 ]
Connor, Michael J., Jr. [5 ]
Winstead, P. Shane [4 ]
机构
[1] Emory Univ Hosp, Dept Pharmaceut Serv, Atlanta, GA 30322 USA
[2] Mercer Coll Pharm & Hlth Sci, Atlanta, GA USA
[3] Nephrol Associates Lexington, Lexington, KY USA
[4] Univ Kentucky HealthCare, Dept Pharm Serv, Lexington, KY USA
[5] Emory Univ, Div Pulm, Atlanta, GA 30322 USA
关键词
RENAL-REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS; MIDDLE-MOLECULE CLEARANCE; ACUTE KIDNEY INJURY; PHARMACOKINETICS; FAILURE; PRINCIPLES; INTENSITY; STANDARD; DOSAGES;
D O I
10.1345/aph.1Q488
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report the pharmacokinetic and pharmacodynamic properties of vancomycin in 4 patients undergoing high-volume continuous venovenous hemofiltration (CVVH). CASE SUMMARY: Data from 4 patients prescribed high-volume CVVH for acute renal failure treated with vancomycin were analyzed. Vancomycin plasma concentrations were measured 4 and 24 hours after the end of a 1-hour vancomycin infusion. The mean therapy fluid rate on initiation of vancomycin was 56.2 mL/kg/h (range 48.0-65.5). The mean loading dose of vancomycin was 18.3 mg/kg (range 14.7-19.7). Median vancomycin concentration 4 hours after the dose was 18.1 mg/L (range 13.1-30.0). At 24 hours after the dose, only 1 patient had a detectable vancomycin concentration (5.2 mg/L). DISCUSSION: There was a large variability in the clearance of vancomycin in this patient population. Current strategies for dosing vancomycin may lead to subtherapeutic trough concentrations. Vancomycin dosing in this patient population should be based on a detailed assessment of the CVVH prescription, vancomycin concentrations, and clinical needs and response. CONCLUSIONS: An initial vancomycin dose of 20-25 mg/kg with frequent monitoring and adjustment is recommended for patients receiving high-volume CVVH.
引用
收藏
页码:E14 / U21
页数:6
相关论文
共 37 条
[2]  
[Anonymous], KIDNEY INT S72
[3]   Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 Patients Treated with Concomitant CRRT [J].
Bauer, Seth R. ;
Salem, Charbel ;
Connor, Michael J. ;
Groszek, Joseph ;
Taylor, Maria E. ;
Wei, Peilin ;
Tolwani, Ashita J. ;
Fissell, William H. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (03) :452-457
[4]  
Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413
[5]   Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients [J].
Boereboom, FTJ ;
Ververs, FFT ;
Blankestijn, PJ ;
Savelkoul, TJF ;
van Dijk, A .
INTENSIVE CARE MEDICINE, 1999, 25 (10) :1100-1104
[6]   Principles of antibacterial dosing in continuous renal replacement therapy [J].
Choi, Gordon ;
Gomersall, Charles D. ;
Tian, Qi ;
Joynt, Gavin M. ;
Freebairn, Ross ;
Lipman, Jeffrey .
CRITICAL CARE MEDICINE, 2009, 37 (07) :2268-2282
[7]   Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis [J].
Connor, Michael J., Jr. ;
Salem, Charbel ;
Bauer, Seth R. ;
Hofmann, Christina L. ;
Groszek, Joseph ;
Butler, Robert ;
Rehm, Susan J. ;
Fissell, William H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (02) :557-560
[8]   Staphylococcus aureus with reduced susceptibility to vancomycin [J].
Cosgrove, SE ;
Carroll, KC ;
Perl, TM .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) :539-545
[9]   Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration [J].
DelDot, ME ;
Lipman, J ;
Tett, SE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (03) :259-268
[10]   VANCOMYCIN PHARMACOKINETICS, RENAL HANDLING, AND NONRENAL CLEARANCES IN NORMAL HUMAN-SUBJECTS [J].
GOLPER, TA ;
NOONAN, HM ;
ELZINGA, L ;
GILBERT, D ;
BRUMMETT, R ;
ANDERSON, JL ;
BENNETT, WM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (05) :565-570